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The biogenesis of beige fat is poorly understood. In recent issues ofNature andCell, Brestoff et al. (2014) and
Lee et al. (2015) demonstrate that resident innate lymphoid cells in subcutaneous fat generate and activate
beige adipocytes, producing thermogenesis.The current obesity epidemic has focused
a great deal of interest on the control of
energy homeostasis and the ensuing
adaptive changes that result in obesity’s
many complications. Much of the atten-
tion has centered on adipose tissue,
which can undergo remodeling in
response to nutrient status and ambient
temperature. Adipose tissues (with their
constituent cells-adipocytes) come in
different colors that reflect unique meta-
bolic roles. In the fed state, adipocytes
in white fat depots accumulate triglycer-
ides. Upon exposure to cold, adipocytes
in brown fat depots respond to cold-
induced activation of the sympathetic
nervous system by increasing lipolysis
and upregulating the expression and
activity of the uncoupling protein UCP1
to stimulate thermogenesis. And recent
studies suggest the presence of a third
type of fat cell, termed ‘‘beige,’’ a
brown-like adipocyte that is present
mainly in subcutaneous white fat depots,
derived from unique precursor cells, and
can be induced by various stimuli to also
generate heat (Wu et al., 2013).
The activities of these different fat-cell
types adapt to conditions of metabolic
stress like obesity. Both white and brown
adipocytes accumulate excessive lipid in
states of overnutrition, and the thermo-
genic activity of beige fat appears to be
decreased, while resistance to both insu-
lin and catecholamines develops in all ad-
ipocytes in the obese state. One intrinsic
feature of the obese state that might link
these outcomes is activation of the innate
immune system; numerous studies sug-
gest that obesity-generated inflammation
is strongly associated with, and perhaps
causal to, insulin resistance and type 2
diabetes. This state of low grade, sus-
tained inflammation is accompanied by
macrophage switching in adipose tissue
from a type 2 (or M2) polarization stategenerally associated with tissue surveil-
lance and increased insulin sensitivity, to
a type 1 (or M1) polarization state charac-
terized by secretion of proinflammatory
cytokines that attenuate insulin action
(Lumeng and Saltiel, 2011). Moreover, al-
terations in adipose tissue macrophage
content and polarization state appear to
occur downstream of a coordinated in-
flammatory circuit that includes crosstalk
between infiltrating T cells with a T helper
1 (Th1) cell pattern of activation, and
reduced Th2 cell responses, with contri-
butions from B cells, NK cells, NKT cells,
eosinophils, neutrophils, and mast cells
(Schipper et al., 2012). Thus, the relative
reduction in type 2 immunity might paral-
lel or even generate increased proin-
flammatory macrophage polarization in
obesity, which in turn influences adipo-
cyte function and response to hormones.
Two recent studies have shed light
on a new player in adipocyte regulation
interleukin-33 (IL-33), a member of the
interleukin 1 family of cytokines known
to regulate group 2 innate lymphoid cells
(ILC2s). Previous studies had shown that
IL-33 administration induces production
of Th2 cell-associated cytokines such
as IL-5, IL-13, and IL-10 and leads to
generation of an M2 phenotype of macro-
phages in adipose tissue, along with
reduced adiposity and insulin resistance
(Miller et al., 2010). Brestoff et al., (2014)
and Lee et al. (2015) now clarify the
mechanisms by which ILC2s appear to
exert their interesting effects and suggest
further that these effects are critically
dependent on the browning of white
fat. Chawla’s laboratory had previously
hinted that M2 macrophages and type 2
immune signaling pathways contribute
to the browning of subcutaneous white
fat (Nguyen et al., 2011; Qiu et al.,
2014). They proposed a process in which
cold activates eosinophils, the mainImmunity 4source of IL-4, which in turn directs a
type 2 immune response circuit to recruit
M2 macrophages and induce tyrosine
hydroxylase expression in these cells
to synthesize catecholamines. Catechol-
amines such as norepinephrine activate
b-adrenergic receptors in adipocytes
to turn on the thermogenic program,
including induction of UCP-1. Lee et al.
(2015) now report that activation of
ILC2s is upstream of this process; in
addition to changes in macrophage func-
tion, the IL-4 derived from these cells also
stimulates the proliferation of bipotential
adipocyte precursors (APs) within sub-
cutaneous fat and enhances their differ-
entiation into beige adipocytes. ILC2s
had previously been identified within
lymphoid structures in mouse and human
mesenteric adipose tissues and known to
sustain visceral adipose tissue eosino-
phils and M2 macrophages that function
to improve insulin sensitivity (Molofsky
et al., 2013).
Because ILC2s are sensitive to IL-33,
Lee et al. (2015) administered IL-33 to
mice adapted to thermoneutrality to acti-
vate ILC2s in subcutaneous white fat.
Interestingly, IL-33 treatment induced
the browning or beiging of subcutaneous
fat, increased UCP1 expression, and pro-
moted energy expenditure under thermal
stress. They noted that, at the same
time, IL-33 promoted proliferation of bipo-
tential platelet-derived growth factor re-
ceptor a+ (PDGFRa+) APs. They demon-
strated that PDGFRa+ APs express IL-4
receptor, and ILC2s promoted prolifera-
tion of PDGFRa+ APs in an IL-4 and/or
IL-13-dependent manner. More impor-
tantly, experiments in mice lacking ILC2s
showed that these cells were required
for proliferation of PDGFRa+ APs in
response to IL-33 treatment. Interestingly,
proliferation of PDGFRa+ APs was age-
dependent, because 5-week-old mice2, January 20, 2015 ª2015 Elsevier Inc. 15
Figure 1. Activation of Type 2 Innate Lymphoid Cells Induces Beige Fat Development in
White Adipose Tissue
Although how cold might trigger the pathway is obscure, activation of ILC2s with IL-33 induces beige fat
biogenesis. Once activated, ILC2s secrete IL-5 and/or IL-13 to sustain and stimulate adipose tissue eo-
sinophils and M2 macrophages. Eosinophils produce IL-4, which directly acts on bipotential adipocyte
precursor (AP) cells through IL-4 receptor a (IL-4Ra). This leads to the proliferation and commitment of
Myf5PDGFRa+ APs to beige adipogenic precursors. These cells eventually differentiate into mature
beige adipocyte with increased amounts of UCP1. IL-4 also activates M2 polarized adipose tissue mac-
rophages (M2 ATM) to produce catecholamines that induce and activate beige fat via the beta-adrenergic
receptor pathway. Obesity reduces the activation of ILC2s, and APs are thus induced to differentiate into
white adipocytes for storage of excess energy. ILC2s are also reported to generatemethionine-enkephalin
(MetEnk) in response to IL-33 via induction of the prohormone convertase (PC1). MetEnk can act directly
on beige adipocytes to increase UCP1 and thermogenesis.
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PDGFRa+ APs. While IL-4 signaling
occurred in both myeloid cells and
PDGFRa+ APs, IL-4 was sufficient to
expand the pool of PDGFRa+ APs in a
cell-autonomous manner in subcutane-
ous fat.
PDGFRa+ APs are bipotential cells that
can differentiate into either beige or white
adipocytes (Lee et al., 2012). To address
whether type 2 cytokine signaling also
directs the commitment of PDGFRa+
APs, they showed that treatment of puri-
fied PDGFRa+ APs derived from subcu-16 Immunity 42, January 20, 2015 ª2015 Elstaneous fat in vitrowith IL-4 induced beige
adipocyte markers, whereas mice
with loss of type 2 cytokine signaling
demonstrated impaired expression of
beige precursor cell markers in PDGFRa+
APsanddecreasedcapacity for beige adi-
pogenesis in vivo. Taken together, Lee
et al. (2015) propose that ILC2scoordinate
a complex circuit of pathways involving
the generation of IL-4 through eosinophils
that controls recruitment of specific pre-
cursors for beige adipogenesis, as well
as the generation from M2 macrophages
of catecholamines that acutely stimulateevier Inc.these newly produced beige adipocytes
for thermogenesis.
Brestoff et al. (2014) independently
demonstrated this unique role for IL-33
and ILC2s in the beiging of subcutaneous
white adipose tissue, but focus on a
different mechanism. These investigators
showed that IL-33-deficient mice devel-
oped metabolic abnormalities while on
normal diet, suggesting that this cytokine
plays a key role in maintaining metabolic
health and insulin sensitivity. They also
identified IL-33-responsive ILC2s in hu-
man white fat and showed that activation
was decreased in human obesity, consis-
tent with previous findings on macro-
phage polarization (Lumeng and Saltiel,
2011). IL-33 increased thermogenesis
and energy expenditure in obese mice,
but in contrast to the report by Lee et al.
(2015), the beneficial effects of the cyto-
kine were identical in eosinophil-deficient
mice, suggesting that IL-33 induces beig-
ing independently of eosinophils and IL-4.
In order to elucidate themechanism of the
biological effect of IL-33, they employed
whole-genome expression profiling of
ILC2s and found prohormone convertase
1 (PC1) to be significantly enriched in
ILC2s after treatment with IL-33. PC1 is
an endopeptidase that converts peptide
hormones into their active form, and addi-
tional studies revealed that ILC2s gener-
ated methionine-enkephalin (MetEnk) in
response to IL-33. Further experiments
revealed that MetEnk directly stimulated
UCP1 expression in isolated beige adipo-
cytes and induced browning of white fat.
This is surprising, because this peptide
binds to delta- and mu-opioid receptors,
known to couple to the heterotrimeric G
protein Gi, and thus reduce cAMP levels
in cells, an effect not expected to increase
UCP1 induction or energy expenditure
(Law et al., 2000). However, perhaps other
pathways or cascades are involved
unique to beige adipocytes.
Notwithstanding these questions,
together these papers suggest that bio-
logical regulation of ILC2s with IL-33
administration and activation of a type 2
cytokine signaling network might provide
new insights into how mammals regu-
late thermogenic capacity and adapt
to environmental stresses like overnutri-
tion and cold (Figure 1). Aside from
resolving the issue of the requirement for
eosinophil function in controllingbrowning
of white fat by ILC2s, there are numerous
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First, what is the true physiological role
of type 2 immunity in subcutaneous fat
function? Is IL-33 required or sufficient
for cold adaptation? How do IL-33-defi-
cient mice respond to high-fat diet? IL-33
is produced from a variety of cells, many
of which are found in adipose tissue.
What might trigger its release? Is there a
regulatory pathway involved in its synthe-
sis or secretion that is somehow induced
by cold? How is the pathway downregu-
lated during obesity? Is there a role for
activation of the sympathetic nervous sys-
tem in this process? Among the most
interesting questions are the therapeutic
implications of this work in patients with
obesity and type 2 diabetes, focusing on
these two newpeptides. IL-33 had benefi-
cial effects in these studies on energy
expenditure, and might be cardioprotec-
tive (Sanadaet al., 2007), but is alsoknown
to promote eosinophilia and allergic
inflammation (Molofsky et al., 2013). Met-
Enk is a delta-opioid agonist with a long
history of target discovery for analgesia,depression, and ischemic precondition-
ing, although concerns with side effects
have limited enthusiasm. Also confusing
is the potential mechanism by which this
peptide might exert its effects on fat cells.
Thus, it will be crucial to answer these
questions and elucidate the relative
importance of these pathways compared
to others that increase energy expendi-
ture. In the meantime, it is becoming
increasingly evident that studies at the
intersection of type 2 immunity and energy
metabolism are really heating up.
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